Why is Senores Pharma. falling/rising?

As of 02-Jul, Senores Pharmaceuticals Ltd is currently priced at 580.50, reflecting a decrease of 3.3 points or 0.57%. The stock has been underperforming, having lost 0.6% over the last two days and is currently underperforming its sector by 0.65%. Despite a positive performance over the past week and month, with returns of 1.49% and 12.18% respectively, the stock's recent decline can be attributed to falling investor participation, as evidenced by a 14.28% drop in delivery volume compared to the five-day average. Additionally, while the company has shown healthy long-term growth with net sales increasing at an annual rate of 85.60%, concerns about its expensive valuation and a decrease in institutional investor stakes by 10.3% may be contributing to the current price movement.
In the broader market context, Senores Pharmaceuticals has outperformed the Sensex over the past week and month, but its year-to-date return of 2.04% lags behind the benchmark's 6.75%. The stock's recent struggles, including flat results reported for December 24 and a relatively low return on equity of 7.4%, suggest that while the company has strong growth potential, the market is reacting negatively to its valuation and declining institutional interest. This combination of factors indicates that despite some positive indicators, the stock is facing headwinds that are impacting its price negatively.